DK2219647T4 - Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet - Google Patents

Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet Download PDF

Info

Publication number
DK2219647T4
DK2219647T4 DK08850935.1T DK08850935T DK2219647T4 DK 2219647 T4 DK2219647 T4 DK 2219647T4 DK 08850935 T DK08850935 T DK 08850935T DK 2219647 T4 DK2219647 T4 DK 2219647T4
Authority
DK
Denmark
Prior art keywords
ht1a
activities
therapeutic applications
sert
combined
Prior art date
Application number
DK08850935.1T
Other languages
English (en)
Other versions
DK2219647T3 (da
Inventor
Marianne Dragheim
Aneil Batra
Nicholas Moore
Jin Chon
Original Assignee
Takeda Pharmaceuticals Usa Inc
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2219647(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Usa Inc, H Lundbeck As filed Critical Takeda Pharmaceuticals Usa Inc
Application granted granted Critical
Publication of DK2219647T3 publication Critical patent/DK2219647T3/da
Publication of DK2219647T4 publication Critical patent/DK2219647T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK08850935.1T 2007-11-13 2008-11-12 Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet DK2219647T4 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98771007P 2007-11-13 2007-11-13
DKPA200701607 2007-11-13
US1372207P 2007-12-14 2007-12-14
DKPA200701788 2007-12-14
US9784008P 2008-09-17 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number Publication Date
DK2219647T3 DK2219647T3 (da) 2012-03-19
DK2219647T4 true DK2219647T4 (da) 2020-09-28

Family

ID=40170671

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08850935.1T DK2219647T4 (da) 2007-11-13 2008-11-12 Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
DK11193237.2T DK2431039T3 (da) 2007-11-13 2008-11-12 Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11193237.2T DK2431039T3 (da) 2007-11-13 2008-11-12 Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Country Status (30)

Country Link
US (5) US9278096B2 (da)
EP (3) EP2431039B1 (da)
JP (2) JP5603244B2 (da)
KR (1) KR101536023B1 (da)
CN (1) CN102014908A (da)
AR (1) AR069260A1 (da)
AT (1) ATE537829T1 (da)
AU (1) AU2008323390B2 (da)
BR (1) BRPI0820474B8 (da)
CA (1) CA2705163C (da)
CL (1) CL2008003363A1 (da)
CO (1) CO6270322A2 (da)
CY (2) CY1112646T1 (da)
DK (2) DK2219647T4 (da)
EA (1) EA027783B1 (da)
ES (2) ES2379419T5 (da)
HR (2) HRP20120144T4 (da)
HU (1) HUE029588T2 (da)
IL (1) IL205466A (da)
LT (1) LT2431039T (da)
MX (1) MX2010004688A (da)
NZ (1) NZ585247A (da)
PL (2) PL2219647T3 (da)
PT (2) PT2431039T (da)
RS (2) RS52256B2 (da)
SG (1) SG10201405001XA (da)
SI (2) SI2219647T2 (da)
TW (1) TW200932233A (da)
WO (1) WO2009062517A1 (da)
ZA (1) ZA201003350B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) * 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
US9274127B2 (en) 2011-07-21 2016-03-01 Meijo University Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood
BR112015013675B1 (pt) * 2012-12-13 2022-04-26 H. Lundbeck A/S Composição compreendendo vortioxetina e donepezil e usos dos mesmos
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
ES2694352T3 (es) * 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
AU2016296205B2 (en) * 2015-07-17 2021-11-11 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CA3026728A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
SI1626720T1 (sl) 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
MX2008016141A (es) * 2006-06-16 2009-02-04 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo.
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin

Also Published As

Publication number Publication date
ZA201003350B (en) 2011-08-31
SI2219647T1 (sl) 2012-06-29
CY1117978T1 (el) 2017-05-17
JP2014193891A (ja) 2014-10-09
US20240082239A1 (en) 2024-03-14
DK2431039T3 (da) 2016-09-26
AU2008323390A1 (en) 2009-05-22
RS52256B (en) 2012-10-31
JP2011503125A (ja) 2011-01-27
US9278096B2 (en) 2016-03-08
HRP20120144T4 (hr) 2020-11-13
ES2379419T5 (es) 2021-05-04
RS52256B2 (sr) 2020-11-30
EP2219647B2 (en) 2020-07-29
AU2008323390B2 (en) 2013-10-24
IL205466A (en) 2014-06-30
US20160228430A1 (en) 2016-08-11
NZ585247A (en) 2012-03-30
CA2705163A1 (en) 2009-05-22
JP5841636B2 (ja) 2016-01-13
ES2379419T3 (es) 2012-04-25
SI2431039T1 (sl) 2017-01-31
US9744166B2 (en) 2017-08-29
EP2431039B1 (en) 2016-07-20
WO2009062517A1 (en) 2009-05-22
BRPI0820474B1 (pt) 2020-08-04
HRP20120144T1 (en) 2012-04-30
CY1112646T1 (el) 2016-02-10
EA027783B1 (ru) 2017-09-29
KR20100099115A (ko) 2010-09-10
ES2591110T3 (es) 2016-11-24
CL2008003363A1 (es) 2009-06-05
PL2431039T3 (pl) 2016-12-30
CO6270322A2 (es) 2011-04-20
PL2219647T3 (pl) 2012-07-31
PT2431039T (pt) 2016-09-29
BRPI0820474B8 (pt) 2021-05-25
CN102014908A (zh) 2011-04-13
IL205466A0 (en) 2010-12-30
US20210093631A1 (en) 2021-04-01
EP2219647B1 (en) 2011-12-21
US20180161321A1 (en) 2018-06-14
RS55147B1 (sr) 2016-12-30
LT2431039T (lt) 2016-10-10
US11628166B2 (en) 2023-04-18
BRPI0820474A2 (pt) 2017-05-23
US20110201617A1 (en) 2011-08-18
KR101536023B9 (ko) 2023-03-29
PT2219647E (pt) 2012-03-16
TW200932233A (en) 2009-08-01
CA2705163C (en) 2013-02-12
JP5603244B2 (ja) 2014-10-08
EP2431039A1 (en) 2012-03-21
SI2219647T2 (sl) 2020-11-30
EA201070598A1 (ru) 2010-10-29
AR069260A1 (es) 2010-01-06
DK2219647T3 (da) 2012-03-19
HUE029588T2 (en) 2017-03-28
EP3115050A1 (en) 2017-01-11
SG10201405001XA (en) 2014-10-30
HRP20161121T1 (hr) 2017-01-27
ATE537829T1 (de) 2012-01-15
MX2010004688A (es) 2010-09-09
KR101536023B1 (ko) 2015-07-10
EP2219647A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
DK2219647T4 (da) Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
DK2205731T3 (da) Anvendelse og fremstilling af citrat-stabile, neutrale metalloproteaser
DK2513023T3 (da) Sammensætninger og anvendelser af cis-1,1,1,4,4,4-hexafluor-2-buten
DK1919904T3 (da) Makrocykliske inhibitorer af hepatitis-c-virus
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
DK2264042T3 (da) Mikronisering af polyoler
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK3494972T3 (da) Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
DK2211901T3 (da) Vaccination med multiple clader af h5-influenza-a-virus
DK2324013T3 (da) Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf
DK2111555T3 (da) Diagnosticering af præeklampsi
DK1981506T3 (da) Langtidsbehandling af HIV-infektion med TMC278
DK1931377T3 (da) CD4+ T epitoper af survivin og deres anvendelse
DK2411009T3 (da) Terapeutiske anvendelser af quinazolindionderivater
DK2475697T3 (da) Associative polyurethaner på basis af cardanol, tilsvarende associative fortykningsmidler og anvendelser deraf
DK2254598T3 (da) Kombination af alfa 7-nikotinagonister og antipsykotika
DK2189537T3 (da) Detektion og behandling af skizofreni
DK2382215T3 (da) Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf
DK2435021T3 (da) Anvendelse af en fast glycosaminoglycan-kombination og en sammensætning, der kan tygges, omfattende den faste kombination
DK2175849T3 (da) Behandling af melanomer
DK2121138T3 (da) Terapeutiske anvendelser af eslicarbazepin
DK2190451T3 (da) Behandling af atherosklerose